Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC
Résumé
Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, RET fusionpositive NSCLC.
Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET fusion-positive NSCLC.
Design: Retrospective study of consecutive patients enrolled in the French expanded-access program for pralsetinib from December 1, 2019, to December 31, 2021.
Domaines
CancerOrigine | Fichiers éditeurs autorisés sur une archive ouverte |
---|---|
licence |